Kidney Center Of Westminster (ARA) is a medicare approved dialysis facility center in Westminster, Colorado and it has 24 dialysis stations. It is located in Jefferson county at 8410 Decatur St Ste 200, Westminster, CO, 80031. You can reach out to the office of Kidney Center Of Westminster (ARA) at (303) 430-6518. This dialysis clinic is managed and/or owned by American Renal Associates. Kidney Center Of Westminster (ARA) has the following ownership type - Profit. It was first certified by medicare in August, 2008. The medicare id for this facility is 062558 and it accepts patients under medicare ESRD program.
| Name | Kidney Center Of Westminster (ARA) |
|---|---|
| Location | 8410 Decatur St Ste 200, Westminster, Colorado |
| No. of Dialysis Stations | 24 |
| Medicare ID | 062558 |
| Managed By | American Renal Associates |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 8410 Decatur St Ste 200, Westminster, Colorado, 80031 | |
| (303) 430-6518 | |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
| NPI Number | 1871774620 |
| Organization Name | Kidney Center Of Westminster |
| Doing Business As | Kidney Center Of Westminster Llc |
| Address | 8410 Decatur St Westminster, Colorado, 80031 |
| Phone Number | (303) 430-6518 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 71% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 13% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 16% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 72% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 14% |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 63% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 22% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 15% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 62% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 14% | 12% |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 79% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 52 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 58 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 140 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1290 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 31 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 299 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 35 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Kidney Center Of Westminster (ARA) with elevated calcium levels.
| Patients with hypercalcemia | 172 |
| Hypercalcemia patient months | 1614 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 178 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 34 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 96 |
| Patient months included in arterial venous fistula and catheter summaries | 804 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 85 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 121 |
| Hospitalization Rate in facility | 193 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 306.3 |
| Hospitalization Rate: Lower Confidence Limit | 130.4 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Kidney Center Of Westminster (ARA) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 27.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.8 |
| Readmission Rate: Lower Confidence Limit | 17.9 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Kidney Center Of Westminster (ARA) get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .67 (As Expected) |
| SIR: Upper Confidence Limit | 1.49 |
| SIR: Lower Confidence Limit | .25 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Kidney Center Of Westminster (ARA)'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 53 |
| Transfusion Rate in facility | 55.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 169.8 |
| Transfusion Rate: Lower Confidence Limit | 20.8 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Kidney Center Of Westminster (ARA) lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 689 |
| Mortality Rate in facility | 15 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19 |
| Mortality Rate: Lower Confidence Limit | 11.7 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago
Westminster Dialysis (DVA) Location: 9053 Harlan St Ste 90, Westminster, Colorado, 80030 Phone: (303) 427-2400 |
Kidney Center Of Westminster (ARA) Location: 8410 Decatur St Ste 200, Westminster, Colorado, 80031 Phone: (303) 430-6518 |
North Metro Denver Dialysis (DVA) Location: 12365 Huron St Ste 500, Westminster, Colorado, 80234 Phone: (303) 451-9093 |
Kidney Center Of Northridge (ARA) Location: 1865 W 121st Ave, Ste 300c, Westminster, Colorado, 80234 Phone: (303) 429-9550 |
News Archive
Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.
An emotionally intelligent, partially autonomous social robot could help children with autism spectrum disorder improve their social skills, according to EU-funded researchers who have been developing the next generation of robot-enhanced therapy.
Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
UCLA scientists have discovered that an overlooked region in brain cells houses a motherlode of mutated genes previously tied to autism. Recently published in Neuron, the finding could provide fresh drug targets and lead to new therapies for the disorder, which affects one in 68 children in the United States.
ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.
› Verified 5 days ago